Licensing Opportunity – Next-Generation CAR-T for Multiple Myeloma
July 8, 2025
Utrecht Holdings is proud to offer a patent-pending CAR-T cell therapy platform developed by researchers at UMC Utrecht.
Utrecht Holdings is proud to offer a patent-pending CAR-T cell therapy platform developed by researchers at UMC Utrecht.
The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2025 Spring edition is NeuroNova Tx! Their groundbreaking stem cell research stimulates brain repair in newborn babies who suffered from brain
As coordinator of the research project Neoliver, Bart Spee leads the international consortium of twelve research institutions and companies. Below is an article in Trouw about the development of the Neoliver.
Mark your calendar for June 18th and 19th, 2025 and join us in the vibrant and historic city of Leuven at the Irish College, Belgium.
Ready to turn your Science into Impact?
Together with the Faculty of Impact, we have organized an information session at our office. Do you have any questions or are you interested? Come by to our office (Bestuursgebouw 0.43) and
We can look back on another great, innovative year.
We thank all researchers from the UU and the UMCU.
Utrecht Holdings and BigCircle Ventures have joined forces to commercialise the catalytic ball milling technology, a breakthrough developed in the lab of Assistant Professor Ina Vollmer at Utrecht University.
UMC Utrecht spin-off company TigaTx, Inc. recently announced that the Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $33.5 million in funding. Separately, TigaTx was awarded a $2 million grant from the National Cancer Institute (NCI), part
Our new colleague, Niek Tettero, started.
Utrecht Holdings is the Utrecht University and UMC Utrecht in-house partner for knowledge transfer and start-ups.
Menu
Visiting address
Contact Us
T: 085 – 087 63 69
BTW-nummers (VAT numbers): UU Holding BV: NL806771604B01 || UMCU Holding BV: NL806125214B01